Research programme: PPAR delta agonists - Eli LillyAlternative Names: Peroxisome proliferator-activated receptor agonists research programme - Eli Lilly
Latest Information Update: 16 Jul 2016
At a glance
- Originator Eli Lilly
- Class Propionic acids
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hyperlipidaemia in USA
- 09 Sep 2004 Preclinical trials in Hyperlipidaemia in USA (unspecified route)